Immunoassay Platform Convergence: From ELISA to Multiplex Immunoassays with the Help of Mix&Go Technology.
3 July 2015
Today, the enzyme-linked immunosorbent assay (ELISA) performed in a 96-well plate remains the mainstay of the clinical laboratory. However, increasingly complex multifactorial diagnosis of cancers, neurodegenerative and autoimmune diseases together with monitoring of complex disorders and individual patient stratification in the new era of personalised healthcare, are stretching the ELISA beyond its limits. To this end, multiplex assays in which multiple analytes can be quantitated within a single patient sample have been gaining market acceptance. This white paper describes how Anteo Technologies’ new Mix&Go Technology is able to attach fragile and delicate biomolecules, such as proteins, to synthetic surfaces, such as glass or plastics, minimising perturbation of tertiary structures.